BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ligand Pharmaceuticals Inc. (LGND) Release: FDA Approves New Fill/Finish Facility For ONTAK(R); Includes Capability For Second-Generation Product Formulation


10/19/2005 5:09:25 PM

SAN DIEGO--(BUSINESS WIRE)--July 5, 2005--Ligand Pharmaceuticals Incorporated (Nasdaq:LGNDE) announced today that the company has received FDA approval for the fill/finish of Ligand's cancer drug ONTAK(R) (denileukin diftitox), at the Hollister-Stier Laboratories facility located in Spokane, Washington. ONTAK bulk drug substance for fill/finish and labeling continues to be manufactured at the Cambrex Bio Science facility located in Hopkinton, Massachusetts. "We submitted the manufacturing supplement for this facility in December 2004 following technology transfer and worked closely with Hollister-Stier and the FDA to obtain this facility approval," said Taylor Crouch, senior vice president, operations and president, international. "We are pleased with the rapid approval and the beginning of this new relationship with a seasoned manufacturing partner for ONTAK, which is our largest-selling oncology product. We expect demand for ONTAK to continue growing, and look forward to working closely with Hollister-Stier on fill/finish of the current formulation of ONTAK and on our second-generation formulation."

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES